Zhejiang Dayang Biotech Group Co (003017) - Net Assets
Based on the latest financial reports, Zhejiang Dayang Biotech Group Co (003017) has net assets worth CN¥1.10 Billion CNY (≈ $161.25 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.75 Billion ≈ $256.49 Million USD) and total liabilities (CN¥650.82 Million ≈ $95.23 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zhejiang Dayang Biotech Group Co liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.10 Billion |
| % of Total Assets | 62.87% |
| Annual Growth Rate | 16.99% |
| 5-Year Change | 9.92% |
| 10-Year Change | 402.06% |
| Growth Volatility | 26.8 |
Zhejiang Dayang Biotech Group Co - Net Assets Trend (2013–2024)
This chart illustrates how Zhejiang Dayang Biotech Group Co's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Zhejiang Dayang Biotech Group Co for the complete picture of this company's asset base.
Annual Net Assets for Zhejiang Dayang Biotech Group Co (2013–2024)
The table below shows the annual net assets of Zhejiang Dayang Biotech Group Co from 2013 to 2024. For live valuation and market cap data, see Zhejiang Dayang Biotech Group Co stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.05 Billion ≈ $154.11 Million |
+4.46% |
| 2023-12-31 | CN¥1.01 Billion ≈ $147.53 Million |
+2.35% |
| 2022-12-31 | CN¥985.05 Million ≈ $144.14 Million |
-0.57% |
| 2021-12-31 | CN¥990.71 Million ≈ $144.97 Million |
+3.40% |
| 2020-12-31 | CN¥958.13 Million ≈ $140.20 Million |
+92.36% |
| 2019-12-31 | CN¥498.09 Million ≈ $72.89 Million |
+13.04% |
| 2018-12-31 | CN¥440.62 Million ≈ $64.48 Million |
+30.47% |
| 2017-12-31 | CN¥337.71 Million ≈ $49.42 Million |
+47.25% |
| 2016-12-31 | CN¥229.35 Million ≈ $33.56 Million |
+9.34% |
| 2015-12-31 | CN¥209.76 Million ≈ $30.70 Million |
+6.55% |
| 2014-12-31 | CN¥196.87 Million ≈ $28.81 Million |
+5.04% |
| 2013-12-31 | CN¥187.42 Million ≈ $27.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Dayang Biotech Group Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 548.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥413.77 Million | 39.33% |
| Common Stock | CN¥84.00 Million | 7.98% |
| Other Comprehensive Income | CN¥55.65 Million | 5.29% |
| Other Components | CN¥498.74 Million | 47.40% |
| Total Equity | CN¥1.05 Billion | 100.00% |
Zhejiang Dayang Biotech Group Co Competitors by Market Cap
The table below lists competitors of Zhejiang Dayang Biotech Group Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hemisphere Properties India Limited
NSE:HEMIPROP
|
$394.89 Million |
|
BTQ Technologies Corp.
NEO:BTQ
|
$395.04 Million |
|
Shandong Teamgene Technology Co. Ltd. A
SHG:603151
|
$395.08 Million |
|
Orthopediatrics Corp
NASDAQ:KIDS
|
$395.11 Million |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089
|
$394.80 Million |
|
Pitti Engineering Limited
NSE:PITTIENG
|
$394.74 Million |
|
Chieftek Precision Co Ltd
TW:1597
|
$394.51 Million |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
$394.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Dayang Biotech Group Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,008,207,423 to 1,052,160,614, a change of 43,953,191 (4.4%).
- Net income of 63,746,338 contributed positively to equity growth.
- Dividend payments of 42,707,190 reduced retained earnings.
- Share repurchases of 41,955,472 reduced equity.
- Other comprehensive income increased equity by 13,605,008.
- Other factors increased equity by 51,264,507.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥63.75 Million | +6.06% |
| Dividends Paid | CN¥42.71 Million | -4.06% |
| Share Repurchases | CN¥41.96 Million | -3.99% |
| Other Comprehensive Income | CN¥13.61 Million | +1.29% |
| Other Changes | CN¥51.26 Million | +4.87% |
| Total Change | CN¥- | 4.36% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Dayang Biotech Group Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.50x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.39x to 2.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥3.83 | CN¥32.12 | x |
| 2014-12-31 | CN¥4.20 | CN¥32.12 | x |
| 2015-12-31 | CN¥4.35 | CN¥32.12 | x |
| 2016-12-31 | CN¥4.89 | CN¥32.12 | x |
| 2017-12-31 | CN¥6.24 | CN¥32.12 | x |
| 2018-12-31 | CN¥7.51 | CN¥32.12 | x |
| 2019-12-31 | CN¥7.92 | CN¥32.12 | x |
| 2020-12-31 | CN¥14.42 | CN¥32.12 | x |
| 2021-12-31 | CN¥11.79 | CN¥32.12 | x |
| 2022-12-31 | CN¥12.08 | CN¥32.12 | x |
| 2023-12-31 | CN¥12.49 | CN¥32.12 | x |
| 2024-12-31 | CN¥12.83 | CN¥32.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Dayang Biotech Group Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.06%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.01%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.57x
- Recent ROE (6.06%) is below the historical average (11.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.93% | 5.27% | 1.13x | 2.50x | CN¥8.70 Million |
| 2014 | 14.45% | 6.12% | 0.99x | 2.39x | CN¥8.65 Million |
| 2015 | 11.83% | 5.28% | 0.98x | 2.29x | CN¥3.66 Million |
| 2016 | 12.57% | 6.53% | 0.95x | 2.04x | CN¥5.89 Million |
| 2017 | 14.88% | 9.06% | 1.08x | 1.52x | CN¥16.48 Million |
| 2018 | 16.07% | 12.12% | 0.97x | 1.37x | CN¥26.73 Million |
| 2019 | 15.96% | 12.79% | 0.96x | 1.30x | CN¥29.69 Million |
| 2020 | 9.56% | 13.50% | 0.55x | 1.28x | CN¥-4.21 Million |
| 2021 | 7.07% | 8.94% | 0.57x | 1.39x | CN¥-29.06 Million |
| 2022 | 8.20% | 7.63% | 0.70x | 1.53x | CN¥-17.78 Million |
| 2023 | 4.96% | 5.44% | 0.59x | 1.53x | CN¥-50.81 Million |
| 2024 | 6.06% | 7.01% | 0.55x | 1.57x | CN¥-41.47 Million |
Industry Comparison
This section compares Zhejiang Dayang Biotech Group Co's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $2,526,275,526
- Average return on equity (ROE) among peers: 14.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Dayang Biotech Group Co (003017) | CN¥1.10 Billion | 14.93% | 0.59x | $394.81 Million |
| North Huajin Chemical Industries Co Ltd (000059) | $12.66 Billion | 14.57% | 1.45x | $1.33 Billion |
| Sichuan Chemical Co Ltd (000155) | $7.35 Billion | 4.73% | 1.50x | $4.71 Billion |
| Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301) | $246.65 Million | 3.47% | 1.71x | $12.84 Billion |
| Zangge Holding Co Ltd (000408) | $477.67 Million | 1.53% | 1.45x | $20.51 Billion |
| Sichuan Jinlu Group Co Ltd (000510) | $1.17 Billion | 5.97% | 1.33x | $1.34 Billion |
| Jilin Gpro Titanium Industry Co Ltd (000545) | $313.50 Million | 0.80% | 0.55x | $436.10 Million |
| Aoyuan Beauty Valley Technology Co Ltd (000615) | $54.68 Million | 39.27% | 1.16x | $871.02 Million |
| Ningxia Younglight Chemicals Co Ltd (000635) | $2.67 Billion | 1.91% | 0.16x | $470.62 Million |
| Maoming Petro-Chemical Shihua Co Ltd (000637) | $220.98 Million | 19.06% | 0.40x | $366.68 Million |
| Inner Mongolia Yuan Xing Energy Co Ltd (000683) | $93.73 Million | 50.32% | 1.49x | $4.87 Billion |
About Zhejiang Dayang Biotech Group Co
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium carbonate and chloride, ammonium chloride, and bicarbonate food and feed additives; industrial grade potassium carbonate and bicarbonate; and agricultural and industrial grade ammonium chloride. It also provide… Read more